Tocilizumab for the treatment of COVID-19: Evidence review of the clinical benefit and harm

Parrish, AReubenson, GBlockman, MCohen, KGray, AKredo, TDe Waal, RMaartens, GNel, JRees, H2024-10-042024-10-042021-05-26https://hdl.handle.net/11288/597706enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/Immunosuppressive drugTocilizumabRapid review of TocilizumabDrug TherapyPharmacyPandemicsCOVID-19Tocilizumab for the treatment of COVID-19: Evidence review of the clinical benefit and harmTechnical Report